Denosumab versus zoledronic acid: analgesic and survival impact of an extended treatment regimen beyond 2 years in breast cancer
These findings highlight the importance for clinicians to carefully consider these differences when selecting bone-modifying agents for patients with cancer-induced bone pain. Prospective studies are needed to confirm the survival benefit of Dmab.
Authors
- Paola Bracchi
- Francesca Ricchini (ORCID: https://orcid.org/0000-0002-5868-3954)
- Augusto Caraceni (ORCID: https://orcid.org/0000-0002-0375-6204)
- Luca Zambelli
- Rosalba Miceli (ORCID: https://orcid.org/0000-0003-0954-375X)
- Ernesto Zecca (ORCID: https://orcid.org/0000-0003-1689-0370)
- Giacomo Massa (ORCID: https://orcid.org/0000-0003-4637-9821)
- Gabriele Tinè (ORCID: https://orcid.org/0000-0003-1762-1375)
- Silvia Lo Dico
- Alessandra Pigni (ORCID: https://orcid.org/0000-0003-1869-965X)
- Gabriella Mariani (ORCID: https://orcid.org/0000-0001-7733-3143)
Institutions
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- The Breast
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.breast.2025.104596
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00